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Abstract
Background: Boswellic acids are pentacyclic triterpenes, which are produced in plants belonging to the genus
Boswellia. Boswellic acids appear in the resin exudates of the plant and it makes up 25-35% of the resin. b-
boswellic acid, 11-keto-b-boswellic acid and acetyl-11-keto-b-boswellic acid have been implicated in apoptosis of
cancer cells, particularly that of brain tumors and cells affected by leukemia or colon cancer. These molecules are
also associated with potent antimicrobial activities. The present study describes the antimicrobial activities of
boswellic acid molecules against 112 pathogenic bacterial isolates including ATCC strains. Acetyl-11-keto-b-
boswellic acid (AKBA), which exhibited the most potent antibacterial activity, was further evaluated in time kill
studies, postantibiotic effect (PAE) and biofilm susceptibility assay. The mechanism of action of AKBA was
investigated by propidium iodide uptake, leakage of 260 and 280 nm absorbing material assays.
Results: AKBA was found to be the most active compound showing an MIC range of 2-8 μg/ml against the entire
gram positive bacterial pathogens tested. It exhibited concentration dependent killing of Staphylococcus aureus
ATCC 29213 up to 8 × MIC and also demonstrated postantibiotic effect (PAE) of 4.8 h at 2 × MIC. Furthermore,
AKBA inhibited the formation of biofilms generated by S. aureus and Staphylococcus epidermidis and also reduced
the preformed biofilms by these bacteria. Increased uptake of propidium iodide and leakage of 260 and 280 nm
absorbing material by AKBA treated cells of S aureus indicating that the antibacterial mode of action of AKBA
probably occurred via disruption of microbial membrane structure.
Conclusions: This study supported the potential use of AKBA in treating S. aureus infections. AKBA can be further
exploited to evolve potential lead compounds in the discovery of new anti-Gram-positive and anti-biofilm agents.
Background
Nosocomial infections pose a significant threat to
patients worldwide. Gram-positive bacterial pathogens
are a significant cause of nosocomial infections that are
important causes of morbidity and mortality [1]. Gram-
positive bacterial pathogens such as Staphylococcus aur-
eus, Streptococcus pneumonia and Enterococcus faecalis
are clinically significant and the antibiotic resistance in
these pathogens has become one of the major worldwide
health problems. The emergence of methicillin-resistant
Staphylococcus aureus (MRSA) and vancomycin-resistant
Enterococcus faecium (VRE) are the major clinical
concerns today [2]. The recent appearance vancomycin-
intermediate resistant (VISA) and vancomycin-resistant
S. aureus isolates (VRSA) in many countries is the latest
development in antibiotic resistance [3]. MRSA has now
exerted its own impact upon the mortality rate. The aver-
age mortality rate from a recent meta-analysis of 30
studies was ≈36% compared against a mortality rate of
≈24% from septicemia caused by methicillin-susceptible
S. aureus [4].
Biofilms are communities of surface-associated micro-
organisms embedded in a self-produced extracellular
polymeric matrix that are notoriously difficult to eradi-
cate and are a source of many recalcitrant infections
[5-9]. Staphylococci are known to form biofilms on an
implanted medical device or damaged tissues and these
biofilms are difficult to disrupt [10]. Biofilm infections
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resistance [11,12].
Boswellic acids are the major constituents of the gum
derived from the plant Boswellia serrata Roxb. ex
Colebr. (family Burseraceae, Syn. B. glabra). The gum
resin comprises of b-boswellic acids as the main triter-
penic acid along with 11-keto-b-boswellic acids and
their acetates [13]. The gum exudate is known for its
anti-inflammatory properties in the Ayurvedic system of
medicines [14,15]. The alcoholic extract of the gum is
used for the treatment of adjuvant arthritis [16]. It has
synergistic effect with glucosamine, an anti-inflamma-
tory and anti-arthritic agent [17]. Acetyl-11-keto-b-
boswellic acid (AKBA), a component of the gum
exudate is a pentacyclic terpenoid and is reported to be
active against a large number of inflammatory diseases
[18,19] including cancer, arthritis, chronic colitis, ulcera-
tive colitis, Crohn’s disease, and bronchial asthma
[20-22]. In spite of these therapeutic effects of boswellic
acids, little is known about their antibacterial activity
and the active principle responsible. The aim of this
study was to evaluate the antibacterial activity of acetyl-
11-keto-b-boswellic acid and its effect on biofilms
generated by S. aureus and Staphylococcus epidermidis.
Results
Minimum inhibitory concentrations (MIC) and minimum
bactericidal concentrations (MBC) of boswellic acids
The in vitro antibacterial activities of boswellic acids
were tested on a group of clinically significant Gram-
positive and Gram-negative bacteria (Table 1). AKBA
was the most active of the four boswellic acids against
the bacterial pathogens. However the activity of AKBA
was limited to Gram-positiveb a c t e r i ao n l ya si t sM I C
was >128 μg/ml against Escherichia coli ATCC 25292
and Pseudomonas aeruginosa ATCC 27853 (Gram-nega-
tive pathogens used in this study). AKBA exhibited MIC
ranging from 2-8 μg/ml against all the Gram-positive
clinical isolates tested, whereas 11-keto-b-boswellic acid
(KBA) and b-boswellic acid (BA) exhibited moderate
Gram-positive antibacterial activity (MIC ≈ 8-64 μg/ml).
Acetyl-b-boswellic acid (ABA) on the other hand was
completely devoid of antibacterial activity upto the
tested concentration of 128 μg/ml. All the compounds
were bacteriostatic in nature and exhibited an MBC
>128 μg/ml. Since AKBA was found to be the most
active boswellic acid compound against Gram-positive
bacterial pathogens, further in vitro studies were per-
formed on this compound against clinically important
S. aureus and S. epidermidis.
Postantibiotic Effect (PAEs)
The PAE of AKBA was determined on S. aureus ATCC
29213 (Table 2). The PAE induced by AKBA was con-
centration dependent, with duration 3.0 ± 0.1 h at 1 ×
M I Cw h i l ea t2×M I Ci tw a s4 . 8±0 . 1h .C i p r o f l o x a c i n
was used as control drug in the study and it exhibited a
PAE of 1.4 ± 0.05 h at 1 × MIC while at 2 × MIC it was
2.2 ± 0.1 h (0.5 μg/ml). The PAEs of AKBA were signifi-
cantly higher than the ciprofloxacin against S. aureus
(P < 0.05).
Time-kill kinetic studies
The time-kill kinetic studies of AKBA were performed
on S. aureus ATCC 29213 (Figure 1). It showed bacter-
iostatic activity at all the tested concentrations. The
maximum effect of AKBA was observed at 16 and
32 μg/ml exhibiting a ≈2l o g 10 reduction in the viability
of S. aureus cells when compared with non treated con-
trols (P < 0.05) at four and eight times it’sM I Co v e ra
period of 24 h study.
Biofilm inhibition and reduction
AKBA effectively inhibited the formation of S. aureus
and S. epidermidis biofilms, with 50% biofilm inhibition
concentration (MBIC50) from 16-32 μg/ml (as derived
from Figure 2A) which is in the range of 4 × MIC and
8 × MIC respectively. AKBA also effectively eradicated
Table 1 Antibacterial activity of boswellic acid molecules against bacterial pathogens
Organisms (CI
n) KBA AKBA BA ABA
Ciprofloxacin MIC
a MIC
a MIC
a MIC
a MBC
b
S. aureus ATCC-29213 0.25 16 2 32 >128 >128
MRSA ATCC 3591, (50) 8->16 16-32 2-4 32-64 >128 >128
E. faecalis ATCC 29212, (22) 0.25-16 16-32 4-8 8-16 >128 >128
E. faecium ATCC 8042, (18) 0.25-16 16-32 4-8 8-16 >128 >128
S. epidermidis ATCC 12228,(12) 0.25->16 8-16 4-8 32-64 >128 >128
Vancomycin resistant E. faecalis (10) >16 8-16 2-8 8-16 >128 >128
E. coli ATCC 25292 0.03 >128 >128 >128 >128 >128
P. aeruginosa ATCC 27853 0.12 >128 >128 >128 >128 >128
MICs and MBCs of boswellic acid molecules were determined using CLSI guidelines against 115 clinical isolates including ATCC strains.
aMinimum Inhibitory
Concentration (μg/ml);
bMinimum Bactericidal Concentration (μg/ml); CI = Clinical isolates; n = number of clinical isolates.
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centration (MBRC50) ranged from 32-64 μg/ml for both
the bacterial isolates (Figure 2B).
Effect of AKBA on membrane integrity
In order to investigate the antibacterial action of AKBA
on the bacterial membrane integrity, the cell suspension
of S. aureus ATCC 29213 was exposed to a concentra-
tion of 64 μg/ml AKBA for 60 and 120 min followed by
staining with propidium iodide (nucleic acid stain). The
AKBA exposure resulted in bacterial cell membrane dis-
ruption as evident from the increased uptake of propi-
dium iodide in comparison to the unexposed cells (P <
0.05) (Figure 3). In addition, the membrane leakage
assay illustrated the cytoplasmic membrane damage of
S. aureus. The amount of 260 and 280 nm absorbing
material in S. aureus cell supernatants treated with
AKBA (relative to the total released upon complete cell
lysis) was 12 and 15% at 90 min while it was 15 and
19% at 120 min respectively (Figure 4), which was sig-
nificantly higher than the untreated control (P < 0.05).
Discussion and conclusion
The gum exudate or the resin obtained from the bark of
Boswellia serrata has been widely used by the practi-
tioners of the Indian systems of medicine for various
medical conditions such as arthritis, asthma, ulcers, and
skin diseases; currently it is being extensively used in
various formulations for the treatment of inflammation
related disorders [13-15]. The major chemical compo-
nents of gum resin can be divided into three groups:
volatile oils or lower terpenoids, higher terpenoids, and
carbohydrates. The higher terpenoids comprises of
b-boswellic acids as the main triterpenic acid along with
11-keto-b-boswellic acids and their acetates [23].
The in vitro antibacterial activity results of four bos-
wellic acid compounds revealed AKBA to be the most
potent antibacterial compound against Gram-positive
pathogens, but it showed no significant antibacterial
activity (MIC >128 μg/ml) against the Gram negative
bacteria. AKBA exerted bacteriostatic antibacterial activ-
ity against S. aureus ATCC 29213 (Figure 1) and exhib-
ited a good PAE of 4.8 h at 2 × MIC concentration.
Staphylococci cause a large percentage of catheter asso-
ciated infections, and like many other pathogens, rather
Table 2 PAEs of Acetyl-11-keto-b-boswellic acid against
S. aureus ATCC 29213
Compounds Mean PAE (h) ± SD on:
1 × MIC 2 × MIC
Acetyl-11-keto-b-boswellic acid 3.0 ± 0.1
a 4.8 ± 0.1
b
Ciprofloxacin 1.4 ± 0.05
a 2.2 ± 0.1
b
The PAEs were monitored by viable count of S. aureus after 2 h exposure to
concentrations equal to MIC and 2 × MIC of antimicrobials (AKBA and
ciprofloxacin). Values in the same column followed by the same superscripts
are significantly different from each other (P < 0.05; Student’s t test). PAE, Post
antibiotic effect.
Figure 1 Effect of AKBA at different concentrations (8, 16 and 32 μg/ml) on the cell viabilty of S. aureus ATCC 29213. S. aureus cells
without AKBA served as control. The effect of AKBA was observed bacteriostatic at all tested concentrations when compared with non treated
control (P < 0.05) over a period of 24 h study. Each time point represents the mean log10 standard deviations (±SD) of three different
experiments performed in duplicate. *, P < 0.05; (Student’s t test).
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Page 3 of 9than living as free planktonic cells within the host they
tend to form a multilayered community of sessile bac-
terial cells known as a biofilm on medical implants or
damaged tissue [7,24,12]. Biofilm infections are difficult
to treat due to their inherent antibiotic resistance
[7,12,25]. AKBA effectively inhibited the staphylococcal
biofilm and also reduced the preformed biofilm of these
bacterial pathogens (P < 0.01). To our knowledge, this is
the first report to provide the evidence that AKBA can
prevent as well as reduce the S. aureus and S. epidermi-
dis generated biofilms.
AKBA is reported to be active against a large number
of inflammatory diseases, cancer, arthritis, chronic coli-
tis, ulcerative colitis, Crohn’s disease, and bronchial
asthma [21,26,20,27,28]. The anticancer activity of
AKBA is attributed to the inhibitory effect on the lipox-
ygenases leading to the inhibition of cell proliferation
and induction of apoptosis in tumor cells [29]. There
A 
B 
Figure 2 Effect of AKBA on the biofilm formation (A) and preformed biofilm (B) by S. aureus ATCC 29213 and S. epidermidis ATCC
12228. After incubation, the biofilms were stained with crystal violet and the optical density of stained adherent bacteria was determined with
a multidetection microplate reader at a wavelength of 595 nm (OD595). The results are expressed as average optical density readings for crystal
violet assays compared to growth control. The biofilm of S. aureus and S. epidermidis were significantly inhibited (A) and reduced (B) compared
with those of bacteria without AKBA (P < 0.01). Values are mean (±SD) from four independent determinations. *, P < 0.01 (Student’s t test).
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activity of oleo-gum resin extracts and oleo-gum resin
essential oils from Boswellia spp. (Burseraceae) [30-32].
Weckessera et al. [33] reported the antibacterial activity
of Boswellia dry extract and keto-ß-boswellic acid. Their
findings revealed that the extract was highly effective
against selected aerobic and anaerobic bacteria such
as Streptococcus, Corynebacteria, C. perfringens and
P. acnes; whereas KBA was not effective against these
pathogens, suggesting that the effective components are
other boswellic acids or essential oils contained in the
extract. In this study, we extensively evaluated the bos-
wellic acids for the antibacterial activity and further for
the first time established that AKBA is the single most
potent antibacterial compound present in the gum exu-
dates of Boswellia serrata.
We further investigated the effect of AKBA on the bac-
terial cell membrane integrity through propidium iodide
uptake assay. Propidium iodide is fluorescent nucleic acid
stain that binds to DNA by intercalating between the
bases with little or no sequence preference. It is mem-
brane impermeant and generally excluded from viable
cells. The increased uptake of propidium iodide in the
AKBA treated cells of Sa u r e u sin our study indicated
that AKBA altered the cell membrane structure, resulting
in the disruption of the permeability barrier of microbial
membrane structures. Leakage of cytosolic constituents
(260 and 280 nm absorbing materials) from S. aureus
cells in the presence 64 μg/ml AKBA over a period of
two h was significantly higher than background levels
(P < 0.05). These observations indicate that the antimi-
crobial activity of AKBA results from its ability to disrupt
the permeability barrier of microbial membrane struc-
tures. The lack of antibacterial activity of AKBA against
Gram-negative bacteria may be attributed due to the pre-
sence of lipophilic outer membrane. This outer layer of
the Gram-negative outer membrane is composed primar-
ily of lipopolysaccharide molecules and forms a hydro-
philic permeability barrier providing protection against
t h ee f f e c t so fh i g h l yh y d r o p h o b i cc o m p o u n d s[ 3 4 , 3 5 ] .
This may be the probable explanation of the resistance of
Gram-negative bacteria to lipophilic AKBA. Similar
Figure 3 Uptake of propidium iodide in cell of S. aureus ATCC
29213. Cells of S. aureus were treated with AKBA at 64 μg/ml for 60
and 120 min. Control group included cells untreated with AKBA.
AKBA treated cells significantly increases the fluorescence compared
with untreated control (P < 0.05). Data represent the mean and
standard deviations (±SD) of two different experiments performed
in triplicate. *, P < 0.05 (Student’s t test).
Figure 4 Effect of AKBA on the leakage of 260 and 280 nm absorbing materials in S. aureus ATCC cells. Control group (treated with lytic
enzymes and considered as 100% leakage) and treated with AKBA at 64 μg/ml for 90 and 120 min. No compound added served as untreated
control. Values are means (±SD) from three independent determinations. *, P < 0.05 (Student’s t test), AKBA treated group compared to
untreated control group.
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lipohilic terpenes such as carvacrol, thymol, eugenol, ger-
aniol, linalyl acetate, (-) menthol and bakuchiol have
reported low sensitivities against Gram-negative bacteria
[36-38].
Gum resin of boswellia is included in the list of sub-
stances Generally Recognized As Safe (GRAS), thereby
permitting its use as food additive by US FDA. Boswellic
acid extract and AKBA have also been reported to be
safe and exert minimal toxicity on human skin cells
[39]. The recent study indicates that B. serrata is non-
mutagenic in Ames test, and is non-clastogenic in
in vitro chromosomal aberration study [40]. Oral pre-
parations of Boswellic serrata extract containing AKBA
are sold in the market as over the counter (OTC) anti-
inflammatory formulations and are considered to be
quite safe [41]. The ancient Indian system of medicine
(Ayurveda) claims these preparations to be safe and
effective dietary supplement against joint disorders
[42,14,15]. Preliminary pharmacokinetic studies carried
out in humans yielded low concentrations of boswellic
acids in plasma [43-45]. In the study reported by Bue-
chele and Simmet [44] AKBA was found in plasma at a
concentration of 0.1 μM after the daily intake of 4 ×
786 mg Boswellia extract for 10 days. In accordance
with the observations made in humans, KBA and AKBA
were detected at a concentration of 0.4 and 0.2 μM,
respectively; in rat plasma following single oral dose
administration of 240 mg/kg Boswellia serrata extract
[46]. Further attempts should be made to improve the
bioavailability of AKBA through lipid based delivery sys-
tems. As the literature suggested that the intake of a
high fat meal increases three to fivefold in the plasma
concentrations of boswellic acid molecules [47].
In addition to the above reported usage and safety
associated with AKBA, the potent antibacterial activity
reported in this study warrants that the structure of
AKBA can be further exploited to evolve potential lead
compounds in the discovery of new anti-Gram-positive
and anti-biofilm agents.
Methods
Extraction and isolation of boswellic acid molecules from
gum resin of Boswellia serrata
BA, KBA, ABA and AKBA were obtained from Bio-
organic Chemistry Division of Indian Institute of Inte-
grative Medicine Jammu, India. The extraction, isolation,
and quantification of these compounds from gum resin
of Boswellia serrata were described in our previous
study [17,23].
Bacterial strains and culture conditions
The bacterial strains used in this study were S. aureus
ATCC 29213, methicillin-resistant S. aureus (MRSA)
ATCC 33591, E. faecalis ATCC 29212, E. faecium
ATCC 8042, S. epidermidis ATCC 12228, E. coli
ATCC 25292, P. aeruginosa ATCC 27853 and 112 iso-
lates of various bacterial pathogens (MRSA 50, E. fae-
calis 22, E. faecium 18, S. epidermidis 12 and
vancomycin resistant E. faecalis 10). All ATCC strains
were procured from the American Type Culture Col-
lection (ATCC, Manassas, VA, USA). Clinical isolates
of all strains were kindly gifted by Ranbaxy Labora-
tories Limited, India and Lupin pharmaceutical, Pune,
India. The cultures were stored at -70°C in trytone
soya broth containing 50% glycerol (vol/vol; Himedia,
Mumbai India) and maintained on tryptic soy agar
(TSA; Difco Laboratories, Detroit, Mich USA).
Determination of minimum inhibitory concentration (MIC)
and minimum bactericidal concentrations (MBC)
MIC was determined as per the guidelines of Clinical
and Laboratory Standards Institute (formerly the
National Committee for Clinical Laboratory Standards)
[48]. Briefly, the bacterial suspensions were prepared by
suspending 18 h grown bacterial culture in sterile nor-
mal saline (0.89% NaCl wt/vol; Himedia, Mumbai India).
The turbidity of the bacterial suspension was adjusted
to 0.5 McFarland standards (equivalent to 1.5 × 10
8 col-
ony forming units (CFU)/ml). The boswellic acids stock
solutions were prepared in 100% dimethyl sulfoxide
(DMSO; Merck, Mumbai India) and 2-fold serial dilu-
tions were prepared in Mueller Hinton Broth (MHB;
Difco Laboratories) in 100 μl volume in 96-well U bot-
tom microtiter plates (Tarson, Mumbai, India). The
above-mentioned bacterial suspension was further
diluted in the MHB and 100 μl volume of this diluted
inoculum was added to each well of the plate resulting
in the final inoculum of 5 × 10
5 CFU/ml in the well and
the final concentration of boswellic acids ranged from
0.25 to 128 μg/ml. Ciprofloxacin was used as standard
antibacterial agent for this study at a concentration ran-
ged from 0.03-16 μg/ml. The plates were incubated at
37°C for 18 h and were visually read for the absence or
presence of turbidity. The minimum concentration of
the compound concentration showing no turbidity was
recorded as MIC. The MBC was determined by spread-
ing 100 μl volume on tryptic soy agar (TSA) plate from
the wells showing no visible growth. The plates were
incubated at 37°C for overnight.
Time kill assay
S. aureus ATCC 29213 was grown in MHB at 37°C for
24 h. The turbidity of the suspension was adjusted to
0.5 McFarland standard (≈ 1.5 × 10
8 CFU/ml) in sterile
normal saline. Two hundred microliters of this suspen-
sion was used to inoculate 20 ml of MHB in conical
flasks containing AKBA in the concentration range of
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study. The flasks were incubated at 37°C. One hundred
microliters samples were taken at 0, 1, 2, 4, 6, 8, 10, and
24 h and the viable counts were determined in triplicate
on TSA. Killing curves were constructed by plotting the
log10 CFU/ml versus time over 24 h [49].
Postantibiotic Effect (PAE)
The PAEs of the AKBA were assessed by the method
described by Craig and Gudmundsson [50]. AKBA was
added at the MIC and 2 × MIC to test tubes containing
≈10
6 CFU/ml of S. aureus ATCC 29213 in MHB broth.
After an exposure of 2 h to the AKBA, samples were
diluted to 1:1,000 in same medium to effectively remove
AKBA. CFU was determined from the sample every
hour until visual cloudiness was noted. The PAE was
calculated by the equation: PAE = T-C , where T repre-
sents the time required for the count in the test culture
to increase 1 log10 CFU/ml above the count observed
immediately after drug removal and C represents the
time required for the count of the untreated control
tube to increase by 1 log10 CFU/ml.
Biofilm susceptibility assay
The biofilms of S. aureus ATCC 29213 and S. epidermi-
dis ATCC 12228 were prepared in 96-well flat-bottom
polystyrene microtiter plates (Tarson, Mumbai, India),
using a previously described method of Wei et al. [51]
with a few modifications. This method was similar to the
MIC assay for planktonic cells. The bacterial suspensions
were prepared from the overnight grown culture and the
turbidity of the suspension was adjusted to 0.7 O.D.610
(≈1×1 0
9 CFU/ml). Twofold serial dilutions of boswellic
acids were prepared in 100 μl volume in tryptone soya
broth (TSB; Difco laboratories) supplemented with 0.5%
glucose in the wells of 96-well flat bottom microtiter
plate. Forty microliters of fresh TSB with 0.5% glucose
was added to each well, followed by the addition of 60 μl
of above bacterial suspension. This resulted in the final
inoculum of 6 × 10
7 CFU/ml in each well: the final con-
centrations of the compounds ranged from (0.12 to
128 μg/ml). The plate was incubated for 18 h at 37°C.
After completion of incubation, the planktonic cells were
removed from each well by washing with phosphate buf-
fer saline (Himedia, Mumbai, India). The biofilms were
fixed with methanol for 15-30 min, stained with 0.1%
(wt/vol) Crystal Violet (Sigma Chemical Co., St Louis,
MO, USA) for 10 min and rinsed thoroughly with water
until the negative control wells appeared colorless. Bio-
film formation was quantified by the addition of 200 μlo f
95% ethanol to the crystal violet stained wells and record-
ing the absorbance at 595 nm (A595)u s i n gam i c r o p l a t e
reader (Multiskan spectrum, Thermo electron, Vantaa,
Finland).
The effect of AKBA was also examined on preformed
biofilms. The biofilms were prepared by inoculating the
suspension of S. aureus and S. epidermidis into the wells
of a polystyrene microtiter plate as mentioned above.
After incubation at 37°C for 18 h, the culture supernatant
from each well was decanted and planktonic cells were
removed by washing the wells with PBS (pH 7.2). Two
fold serial dilution of AKBA was prepared in TSB and 200
μl of each dilution was added to the biofilm in the wells.
The plate was further incubated at 37°C for 18 h. The bio-
film was fixed, stained and quantified as described above.
Propidium iodide uptake assay
The action of AKBA on cell membrane permeability of S.
aureus ATCC 29213 cells was evaluated by the method
as described by Cox et al. [52]. The bacterial cells were
grown overnight in 100 ml of MHB at 37°C, washed and
resuspended in 50-mmol/l sodium phosphate buffer, pH
7·1. The turbidity of the suspension was adjusted to 0.7
O.D.610 (≈1×1 0
9 CFU/ml). One milliliter volume of this
suspension was added to flask containing 19 ml buffer
and 64 μg/ml of AKBA. Following 60 and 120 min incu-
bation at room temperature, 50 μl aliquots were trans-
ferred into Eppendorfs tubes containing 950 μl
phosphate buffer in FACS tubes (Becton Dickinson Bios-
ciences, CA, USA). These tubes were stored on ice and 5
μl of staining solution, consisting of 2.5 mg/ml propi-
dium iodide (Sigma) dissolved in milliQ water, was added
in the final propidium iodide concentration of 10 μg/ml.
The cells were subjected to FACS analysis [53,54], on the
flow cytometer (BD-LSR, Becton Dickinson).
Leakage of 260 and 280 nm absorbing compounds
The release of 260 and 280 nm absorbing compounds
was determined spectrophotometrically [55]. Briefly, cells
suspensions of S. aureus were prepared as for propidium
iodide uptake assay. AKBA was added at 64 μg/ml to the
bacterial suspension (≈1×1 0
9 CFU/ml) and incubated
for 120 min at 37°C. For the complete release of 260 and
280 nm absorbing compounds, the bacterial suspension
(control) was treated with lysozyme (100 μg/ml) at 37°C
for 120 min, followed by sonication. Cell supernatants
were obtained by centrifugation (10,000 g for 10 min).
The absorbance of cell supernatant at 260 and 280 nm
was determined using spectrophotometer (Multiskan
Spectrum). Background leakage rates (no compounds
added) were used as untreated control. The extent of
leakage of 260 and 280 nm absorbing compounds was
expressed as percentage of control (suspension treated
with lysozyme) measured in supernatants.
Statistical analysis
All experiments were carried out in triplicates in at least
three different occasions. Differences between two
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were analyzed by one-way ANOVA for comparison of
multiple means followed by post bonferroni test using
GraphPad Instat2 program (GraphPad software Inc. San
Diego CA). The chosen level of significance for all sta-
tistical tests was P < 0.05.
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